Francois Bertucci
Overview
Explore the profile of Francois Bertucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
416
Citations
10826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferraioli D, Borella F, Meurer M, Lebreton C, Penel N, Bertucci F, et al.
Int J Gynecol Cancer
. 2025 Mar;
:101692.
PMID: 40044476
Objectives: Primary ovarian leiomyosarcomas are exceptionally rare, constituting less than 1% of ovarian tumors, and they typically have a poor prognosis. The available data on the management of these tumors...
2.
Guille A, Adelaide J, Finetti P, Andre F, Birnbaum D, Mamessier E, et al.
Brief Bioinform
. 2025 Jan;
26(1).
PMID: 39828270
By identifying somatic mutations, whole-exome sequencing (WES) has become a technology of choice for the diagnosis and guiding treatment decisions in many cancers. Despite advances in the field of somatic...
3.
Kfoury M, Finetti P, Mamessier E, Bertucci F, Sabatier R
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596024
Antibody-drug conjugates targeting folate receptor alpha (FRα) are a promising treatment for platinum-resistant ovarian cancer (OC) with high FRα expression. Challenges persist in accurately assessing FRα expression levels. Our study...
4.
Rejaibi R, Guille A, Manai M, Adelaide J, Agavnian E, Jelassi A, et al.
Sci Rep
. 2024 Nov;
14(1):28573.
PMID: 39562613
Ovarian cancer (OC) is one of the most common cancers in women, with a high mortality rate. Most of published studies have been focused on Caucasian populations, with the need...
5.
Bertucci F, Guille A, Lerebours F, Ceccarelli M, Syed N, Adelaide J, et al.
J Transl Med
. 2024 Oct;
22(1):969.
PMID: 39465437
Background: Neoadjuvant chemotherapy (NACT) became a standard treatment strategy for patients with inflammatory breast cancer (IBC) because of high disease aggressiveness. However, given the heterogeneity of IBC, no molecular feature...
6.
Lopez M, Crompot E, Josselin E, Farina A, Rubis M, Castellano R, et al.
Cancer Res Commun
. 2024 Oct;
4(11):2998-3012.
PMID: 39440991
ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV...
7.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al.
N Engl J Med
. 2024 Sep;
391(9):789-799.
PMID: 39231341
Background: The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma. Methods: We conducted a...
8.
Blay J, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, et al.
Lancet Oncol
. 2024 Aug;
25(9):1163-1175.
PMID: 39127063
Background: The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes...
9.
Devi G, Pai P, Lee S, Foster M, Sannareddy D, Bertucci F, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):65.
PMID: 39075068
Therapeutic resistance presents a significant hurdle in combating inflammatory breast cancer (IBC), adding to the complexity of its management. To investigate these mechanisms, we conducted a comprehensive analysis using transcriptomic...
10.
Choderlos de Laclos X, Risbourg S, Brennan B, Bertucci F, Gaspar N, Gelderblom H, et al.
Eur J Cancer
. 2024 Jul;
208:114229.
PMID: 39032218
Introduction: Ewing sarcoma (ES), is a rare cancer affecting children, adolescents and adults. After VIDE (vincristine-ifosfamide-doxorobucin-etoposide) induction chemotherapy, Busulfan-Melphalan (BuMel) high-dose chemotherapy followed by autologous hematopoietic stem cells transplantation improved...